172 related articles for article (PubMed ID: 35614373)
1. Investigation of cancer response to chemotherapy: a hybrid multi-scale mathematical and computational model of the tumor microenvironment.
Nikmaneshi MR; Firoozabadi B
Biomech Model Mechanobiol; 2022 Aug; 21(4):1233-1249. PubMed ID: 35614373
[TBL] [Abstract][Full Text] [Related]
2. Chemo-mechanistic multi-scale model of a three-dimensional tumor microenvironment to quantify the chemotherapy response of cancer.
Nikmaneshi MR; Firoozabadi B; Mozafari A
Biotechnol Bioeng; 2021 Oct; 118(10):3871-3887. PubMed ID: 34133020
[TBL] [Abstract][Full Text] [Related]
3. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.
Nikmaneshi MR; Jain RK; Munn LL
PLoS Comput Biol; 2023 Jun; 19(6):e1011131. PubMed ID: 37289729
[TBL] [Abstract][Full Text] [Related]
4. Multi-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapy.
Cai Y; Zhang J; Li Z
Biomed Eng Online; 2016 Dec; 15(Suppl 2):155. PubMed ID: 28155728
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Majidpoor J; Mortezaee K
Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor.
Shen R; Peng L; Zhou W; Wang D; Jiang Q; Ji J; Hu F; Yuan H
J Control Release; 2022 Sep; 349():550-564. PubMed ID: 35841997
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
Mittal K; Ebos J; Rini B
Semin Oncol; 2014 Apr; 41(2):235-51. PubMed ID: 24787295
[TBL] [Abstract][Full Text] [Related]
8. Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.
Abdalla AME; Xiao L; Ullah MW; Yu M; Ouyang C; Yang G
Theranostics; 2018; 8(2):533-548. PubMed ID: 29290825
[TBL] [Abstract][Full Text] [Related]
9. A multi-scale model for determining the effects of pathophysiology and metabolic disorders on tumor growth.
Nikmaneshi MR; Firoozabadi B; Mozafari A; Munn LL
Sci Rep; 2020 Feb; 10(1):3025. PubMed ID: 32080250
[TBL] [Abstract][Full Text] [Related]
10. Modeling three-dimensional invasive solid tumor growth in heterogeneous microenvironment under chemotherapy.
Xie H; Jiao Y; Fan Q; Hai M; Yang J; Hu Z; Yang Y; Shuai J; Chen G; Liu R; Liu L
PLoS One; 2018; 13(10):e0206292. PubMed ID: 30365511
[TBL] [Abstract][Full Text] [Related]
11. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling.
Bodzioch M; Bajger P; Foryś U
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2281-2299. PubMed ID: 34050795
[TBL] [Abstract][Full Text] [Related]
13. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization.
Wang K; Chen Q; Liu N; Zhang J; Pan X
Drug Discov Today; 2021 Nov; 26(11):2743-2753. PubMed ID: 34332098
[TBL] [Abstract][Full Text] [Related]
15. Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.
Lai V; Neshat SY; Rakoski A; Pitingolo J; Doloff JC
Adv Drug Deliv Rev; 2021 Dec; 179():113920. PubMed ID: 34384826
[TBL] [Abstract][Full Text] [Related]
16. Metronomic chemotherapy and nanocarrier platforms.
Abu Lila AS; Ishida T
Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
[TBL] [Abstract][Full Text] [Related]
17. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
18. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.
Li D; Finley SD
Integr Biol (Camb); 2018 Apr; 10(4):253-269. PubMed ID: 29623971
[TBL] [Abstract][Full Text] [Related]
19. In pursuit of new anti-angiogenic therapies for cancer treatment.
Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
[TBL] [Abstract][Full Text] [Related]
20. Normalization of the tumor microvasculature based on targeting and modulation of the tumor microenvironment.
Li Z; Ning F; Wang C; Yu H; Ma Q; Sun Y
Nanoscale; 2021 Oct; 13(41):17254-17271. PubMed ID: 34651623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
